跳到正文
原文
MedPage Today·· 6 天前精选AI 评分76

结直肠癌方案缩短周期维持疗效并减少毒性

Shorter Cycle Maintains Efficacy of Colorectal Cancer Regimen

AI 导读

一项III期PRABITAS试验显示,14天周期的FTD-TPI联合贝伐单抗与标准28天周期非劣效,OS分别为10.3个月和11.3个月,且毒性降低。研究支持该方案作为难治性转移性结直肠癌的首选标准治疗。

推荐理由

研究显示14天周期的FTD-TPI联合贝伐单抗与标准28天周期非劣效,且毒性更低,支持该方案作为难治性转移性结直肠癌的首选标准治疗。

正文 · 原文

— 14-day cycle length for trifluridine-tipiracil plus bevacizumab also limited toxicity

November 13, 2026 • 3 min read

  • A 28-day course of standard treatment for refractory metastatic colorectal cancer is associated with hematologic and gastrointestinal toxicity.
  • A phase III trial showed that a 14-day course of trifluridine-tipiracil and bevacizumab was noninferior to the conventional 28-day course for overall survival.
  • Rates of grade ≥3 neutropenia and grade ≥2 anorexia were reduced in the shorter-course group.

A shorter cycle length for a standard treatment for refractory metastatic colorectal cancer was noninferior to the typical longer length for overall survival (OS), while limiting toxicity, the phase III PRABITAS trial from Japan showed.

Median OS was 10.3 months in patients who received the standard 28-day cycle length of trifluridine-tipiracil (FTD-TPI; Lonsurf) and bevacizumab versus 11.3 months for those who received a 14-day schedule (stratified HR 0.93, 95% CI 0.80-1.08), reported Hiroya Taniguchi, MD, of Aichi Cancer Center Hospital in Nagoya, and colleagues.

This met the prespecified noninferiority margin of below 1.25 for the upper limit of the confidence interval, they noted in The Lancet.

The 12-month OS rates were 44% in the 28-day group and 47.5% in the 14-day group.

Importantly, rates of grade ≥3 neutropenia and grade ≥2 anorexia were reduced in the shorter-course group.

"Taken together with previous evidence, these findings support adoption of the 14-day FTD-TPI plus bevacizumab schedule as the preferred standard of care for refractory metastatic colorectal cancer," Taniguchi and colleagues wrote.

FTD-TPI plus bevacizumab was established as the standard treatment for refractory metastatic colorectal cancer based on results from the phase III SUNLIGHT trial, in which patients treated with the regimen achieved a significant improvement in OS compared with FTD-TPI monotherapy. Data from a real-world analysis supported the SUNLIGHT results.

However, Taniguchi and colleagues noted that while the regimen -- which involves administering FTD-TPI twice daily on days 1-5 and 8-12, and bevacizumab on days 1 and 15 of a 28-day cycle -- was generally tolerable, it "carries a treatment burden that leaves room for further optimization."

In particular, it has been associated with increased hematologic toxicity, including grade ≥3 neutropenia.

"The clinical message stemming from PRABITAS is straightforward," wrote Paolo Ciracì, MD, and Chiara Cremolini, MD, PhD, of Azienda Ospedaliera Universitaria Pisana in Pisa, Italy, in an accompanying commentary. "Simplifying FTD-TPI administration in a 14-day schedule does not compromise treatment efficacy but does reduce the burden of adverse events and also the complexity of treatment delivery."

The study also reflects a move towards a more patient-centered approach by "shifting the focus from which therapies should be used, and in what sequence, to how effective therapies can be delivered to preserve patients' fitness and their ability to remain on treatment and receive subsequent lines," they added.

However, Ciracì and Cremolini noted that it remains an open question whether these results translate into a meaningful improvement in quality of life since Taniguchi and colleagues did not formally assess that endpoint.

Given that a 14-day schedule had been proposed to reduce toxicity, the researchers sought to determine whether the shorter course was noninferior to the conventional 28-day schedule for OS.

PRABITAS was conducted at 178 hospitals in Japan and included 972 patients assigned to receive FTD-TPI (35 mg/m2 orally twice daily) plus bevacizumab (5 mg/kg intravenously) on either a conventional 28-day schedule or a 14-day cycle schedule (FTD-TPI on days 1-5, and bevacizumab on day 1).

Median patient age was 68 years, the majority (57%) were men, and RAS mutations were present in 59% of patients. The median follow-up was 17.9 months.

Looking at secondary endpoints, median progression-free survival was 3.9 months in both groups (stratified HR 0.93, 95% CI 0.81-1.06). The median time to treatment failure was 3.6 months in the 28-day group and 3.8 months in the 14-day group (stratified HR 0.90, 95% CI 0.79-1.03).

Among 906 patients with measurable disease at baseline, the objective response rate was 2.4% in the 28-day group and 1.6% in the 14-day group, with no complete responses observed. The disease control rate was 46.6% and 52.1% in the two groups, respectively.

Grade ≥3 neutropenia occurred in 39% of patients in the 28-day group and 13% in the 14-day group, with grade 4 neutropenia occurring in 8% and 1%, respectively. Febrile neutropenia occurred in 5% of patients in the 28-day group versus 1% in the 14-day group.

Non-hematologic toxicities were also less frequent in the 14-day group.

Grade ≥2 anorexia occurred in 26% of patients in the 28-day group compared with 15% in the 14-day group, while nausea was reported in 18% and 12%, respectively, and diarrhea in 10% and 4%.

Two treatment-related deaths occurred in the 14-day group, including one gastrointestinal hemorrhage and one gastrointestinal perforation, both attributed to bevacizumab.

来源:MedPage Today · medpagetoday.com